As considerable studies have demonstrated gefitinib to be a radiation sensitizer in the treatment of a variety of tumors including NSCLC, head and neck, breast, and colorectal cancers [20,21], we think EGFR-targeted therapy may have strengthened the role of radiation-induced vascular occlusion and subsequent post-ischemic hemorrhage. This evidence concerns the gene EGFR and colorectal cancer.